Maleimido-(EG)3-Propionic Acid (SP-19070)
2015-03-16The most common schemes for forming a well-defined heteroconjugate involve the indirect coupling of an amine group on one biomolecule to a thiol group on a second biomolecule, usually by a two- or three-step reaction sequence with Crosslinking Reagents (Maleimido-Alkyl-Carboxylic acids). Introducing Poly(Ethylene Glycol) chains into the heterobifunctional crosslinkers by Kratz, F. and coworkers [Bioconjugate Chem. 2003, 14(2), 377-387.] will enhance their water solubility. Now SpeedChemical can offer these Maleimido-Poly(Ethylene Glycol) Propionic (or Acetic) Acids products to medicinal chemists and biotechnological chemists. Such as Maleimido-Tri(Ethylene Glycol) Propionic Acis, SP-19070, CAS# 518044-40-1. Please see our Product Section for details.
![](/files/images/201503/160403494408.jpg)
Reference:
(1) Maleimide-oligo(ethylene glycol) Derivatives of Camptothecin as Albumin-Binding Prodrugs: Synthesis and Antitumor Efficacy. Warnecke, A.; Kratz, F. Bioconjugate
Chem., 2003, 14, 377.
Chem., 2003, 14, 377.
(2) Bayer Pharma Aktiengesellschaft: Novel antibody-peptide drug conjugates (ADCs) and their use and preparation. Lerchen, H.-G.; Hammer, S.; Harrenga, A.; Kopitz,
C. C.; Nising, C. F.; Sommer, A.; Stelte-Ludwig, B.; Mahlert, C.; Schuhmacher, J.; Golfier, S.; et al WO 2013087716; WO 2012143497.
C. C.; Nising, C. F.; Sommer, A.; Stelte-Ludwig, B.; Mahlert, C.; Schuhmacher, J.; Golfier, S.; et al WO 2013087716; WO 2012143497.
(3) Pfizer Inc.: Engineered antibody constant regions for site-specific conjugation with therapeutic and for treatment of cancer, autoimmune, inflammatory, infectious or
other disease. Marquette, K.; Bennett, E.; Tchistiakova, L.; Tumey, N. WO 2013093809.
other disease. Marquette, K.; Bennett, E.; Tchistiakova, L.; Tumey, N. WO 2013093809.